HomeBrainCool AB

BrainCool AB

BrainCool AB Announces Statistically Significant Late-Breaking Clinical Data at ESMO Virtual Congress 2020

The data was collected from a Nordic multi-center pivotal trial led by Karolinska University Hospital, Stockholm, that enrolled 182 patients with multiple myeloma or lymphoma who were scheduled to receive high-dose chemotherapy prior to hematopoietic stem cell transplantation.

European Medical Device Firm BrainCool AB Enters US Market with 510(k) Clearance from FDA for IQoolTM System for Temperature Management

Based in Lund, Sweden, Europe, BrainCool AB (publ) (AktieTorget: BRAIN) is a publicly traded medical device company focused on next-generation temperature management systems BrainCool AB, a European medical device firm, has received 510(k) clearance from the US Food...